Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
147 hedge funds and large institutions have $1.69B invested in Audentes Therapeutics, Inc in 2019 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 62 increasing their positions, 34 reducing their positions, and 21 closing their positions.
280% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $2.7M
82% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 34
52% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 21
6% more funds holding
Funds holding: 139 → 147 (+8)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
1% less capital invested
Capital invested by funds: $1.71B → $1.69B (-$15.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$52.6M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$46M |
| 3 |
State Street
Boston,
Massachusetts
|
+$18.1M |
| 4 |
BlackRock
New York
|
+$15.9M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$41.9M |
| 2 |
Jennison Associates
New York
|
-$28.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.9M |
| 4 |
VVM
Versant Venture Management
San Francisco,
California
|
-$9.57M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.71M |
BOLD Hedge Fund Activity: Q2 2019 in Review
147 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q2 2019, worth a combined $1.69B — down 0.91% from $1.71B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new BOLD positions and 21 closed out — a net gain of 11 holders — while 62 added to existing stakes and 34 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $52.6M. The largest seller was Fidelity Investments, cutting an estimated $41.9M.
- 147 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q2 2019, up from 139 in Q1 2019.
- Funds reported $1.69B of Audentes Therapeutics, Inc stock for Q2 2019, down 0.91% quarter-over-quarter.
- 32 funds opened new Audentes Therapeutics, Inc positions in Q2 2019 and 21 closed out, a net change of +11 holders.
- The largest Audentes Therapeutics, Inc buyer in Q2 2019 was Bellevue Group, an estimated $52.6M added.
- The largest Audentes Therapeutics, Inc seller in Q2 2019 was Fidelity Investments, an estimated $41.9M sold.
Based on aggregated 13F filings for Q2 2019.